Product Information
CLONAZEPAM 2 MG ODT is a generic product labeled by Par Health USA, LLC, priced at $0.8792 per EA under NDC 49884031002. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 3, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Par Health USA, LLCNDC
49884031002
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA077171FDA Approved
8/3/2005
TE Code
AB
On Market Since
8/5/2005
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 2 MG ODT has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 17.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8792 per EA |
|---|---|
| All-time high | $1.3975 (Oct 10, 2018) |
| All-time low | $0.6478 (Jan 17, 2024) |
| 52-week high | $1.0328 |
| 52-week low | $0.8327 |
| Median price | $1.0489 |
| Average price | $1.0885 |
| Largest weekly change | +63.3% (Mar 20, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 95% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Par Health USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clonazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 2 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 2 MG ODT, manufactured by Par Health USA, LLC, is $0.8792 per EA (NDC 49884031002), effective Sep 30, 2026.
How has the price of CLONAZEPAM 2 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 2 MG ODT has declined 17.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 2 MG ODT?
Since Nov 28, 2013, the NADAC for CLONAZEPAM 2 MG ODT has ranged from a low of $0.6478 (Jan 17, 2024) to a high of $1.3975 (Oct 10, 2018), with a median of $1.0489 per EA.
Are there cheaper alternatives to CLONAZEPAM 2 MG ODT?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLONAZEPAM 2 MG TABLET, is $0.0402 per EA — about 95% below CLONAZEPAM 2 MG ODT.
Who manufactures CLONAZEPAM 2 MG ODT?
CLONAZEPAM 2 MG ODT (NDC 49884031002) is labeled by Par Health USA, LLC, and CMS classifies it as a generic product.